ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

More than one-third of patients with advanced melanoma were still alive 5 years after starting treatment with the anti-PD-1 immunotherapy nivolumab, according to long-term phase I data.

Researchers at the University of Colorado Cancer have created a new tool that will help oncologists match the right therapy to cancer type based on the patient's genetic data.

Neutralizing intratumoral pH may help improve responses to immunotherapy and improve outcomes with current targeted therapies, according to a study published March 15, 2016, in the journal Cancer Research.

A research team at University of California, Merced has identified a drug that could be effective in targeting melanoma cells.

A 90-year-old woman presents with a lesion in the right forearm. After further assessment, a biopsy is performed. What is your diagnosis?

PRAME mRNA is a biomarker of metastasis risk for patients with class 1 uveal melanoma, according to authors of a retrospective study.

The combination of TriMixDC-MEL and ipilimumab produced durable tumor responses in patients with pretreated advanced melanoma, according to a phase II study.

Pages

Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.